Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71−0.06 (-1.59%)
Close on Nov 16, 2026Market cap $283.06MP/E –Yield –
Fulcrum Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Fulcrum Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $44.98M, down 14.2% year over year. For fiscal 2025 it was $56.10M, down 11.5% from the year before. The highest annual figure on record is $76.78M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.10M | -11.5% |
| FY2024 | Dec 31, 2024 | $63.39M | -11.7% |
| FY2023 | Dec 31, 2023 | $71.80M | -6.5% |
| FY2022 | Dec 31, 2022 | $76.78M | +10.2% |
| FY2021 | Dec 31, 2021 | $69.70M | +18.1% |
| FY2020 | Dec 31, 2020 | $59.04M | -16.9% |
| FY2019 | Dec 31, 2019 | $71.07M | +182.2% |
| FY2018 | Dec 31, 2018 | $25.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.03M | -78.8% |
| Q2 FY2026 | Jun 30, 2026 | $12.44M | -4.2% |
| Q1 FY2026 | Mar 31, 2026 | $14.08M | +5.1% |
| Q4 FY2025 | Dec 31, 2025 | $15.42M | +31.6% |
| Q3 FY2025 | Sep 30, 2025 | $14.30M | -2.3% |
| Q2 FY2025 | Jun 30, 2025 | $12.99M | -24.8% |
| Q1 FY2025 | Mar 31, 2025 | $13.40M | -32.2% |
| Q4 FY2024 | Dec 31, 2024 | $11.71M | -38.3% |
| Q3 FY2024 | Sep 30, 2024 | $14.64M | -19.7% |
| Q2 FY2024 | Jun 30, 2024 | $17.26M | -3.3% |
| Q1 FY2024 | Mar 31, 2024 | $19.77M | +18.3% |
| Q4 FY2023 | Dec 31, 2023 | $19.00M | +2.3% |
| Q3 FY2023 | Sep 30, 2023 | $18.24M | +18.7% |
| Q2 FY2023 | Jun 30, 2023 | $17.85M | -28.7% |
| Q1 FY2023 | Mar 31, 2023 | $16.72M | -6.3% |
| Q4 FY2022 | Dec 31, 2022 | $18.57M | -1.8% |
| Q3 FY2022 | Sep 30, 2022 | $15.37M | -10.0% |
| Q2 FY2022 | Jun 30, 2022 | $25.02M | +44.0% |
| Q1 FY2022 | Mar 31, 2022 | $17.83M | +9.2% |
| Q4 FY2021 | Dec 31, 2021 | $18.91M | +17.1% |
| Q3 FY2021 | Sep 30, 2021 | $17.08M | +9.2% |
| Q2 FY2021 | Jun 30, 2021 | $17.38M | +36.0% |
| Q1 FY2021 | Mar 31, 2021 | $16.33M | +12.8% |
| Q4 FY2020 | Dec 31, 2020 | $16.15M | +33.6% |
| Q3 FY2020 | Sep 30, 2020 | $15.64M | +15.9% |
| Q2 FY2020 | Jun 30, 2020 | $12.78M | +17.6% |
| Q1 FY2020 | Mar 31, 2020 | $14.48M | -58.2% |
| Q4 FY2019 | Dec 31, 2019 | $12.09M | +76.2% |
| Q3 FY2019 | Sep 30, 2019 | $13.50M | +93.8% |
| Q2 FY2019 | Jun 30, 2019 | $10.86M | +87.6% |
| Q1 FY2019 | Mar 31, 2019 | $34.63M | – |
| Q4 FY2018 | Dec 31, 2018 | $6.86M | – |
| Q3 FY2018 | Sep 30, 2018 | $6.96M | – |
| Q2 FY2018 | Jun 30, 2018 | $5.79M | – |
See a number that looks wrong?